Search results
Results from the WOW.Com Content Network
The Breakthrough of the Year is an annual award for the most significant development in scientific research made by the AAAS journal Science, an academic journal covering all branches of science. [1] Originating in 1989 as the Molecule of the Year, [2] and inspired by Time 's Person of the Year, it was renamed the Breakthrough of the Year in 1996.
CRISPR-Cas9 genome editing techniques have many potential applications. The use of the CRISPR-Cas9-gRNA complex for genome editing [10] was the AAAS's choice for Breakthrough of the Year in 2015. [11] Many bioethical concerns have been raised about the prospect of using CRISPR for germline editing, especially in human embryos. [12]
In 2015, together with Emmanuelle Charpentier, she received the Breakthrough Prize in Life Sciences for her contributions to CRISPR/Cas9 genome editing technology. [86] In 2016, together with Charpentier, Feng Zhang , Philippe Horvath and Rodolphe Barrangou , she received the Canada Gairdner International Award . [ 13 ]
That year Marraffini and Sontheimer confirmed that a CRISPR sequence of S. epidermidis targeted DNA and not RNA to prevent conjugation. This finding was at odds with the proposed RNA-interference-like mechanism of CRISPR-Cas immunity, although a CRISPR-Cas system that targets foreign RNA was later found in Pyrococcus furiosus .
The therapy, called Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is the first medicine to be approved in the United States that uses the gene-editing tool CRISPR, which won its ...
Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. This new coverage could also make it easier once CRISPR ...
The CRISPR-Cas system was selected by Science as 2015 Breakthrough of the Year. [ 5 ] As of 2015 [update] four families of engineered nucleases were used: meganucleases , zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALEN), and the clustered regularly interspaced short palindromic repeats ( CRISPR / Cas9 ...
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...